Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486672 | 0.82 | AR (0.49) | TP53POLBMAPTMEN1HTT | |
| SCHEMBL1369152 | 0.82 | PTGDR2 (0.51) | SLC1A5TP53POLBGAAMAPT | |
| SCHEMBL2485943 | 0.81 | SLC1A5 (0.44) | SLC1A5KDM4ETP53POLBGAA | |
| SCHEMBL2487977 | 0.80 | MAPT (0.43) | SLC1A5KDM4ETP53POLBGAA | |
| SCHEMBL1369743 | 0.78 | PTGDR2 (0.48) | TP53 | |
| SCHEMBL1366570 | 0.77 | PARP1 (0.38) | — | |
| SCHEMBL1369731 | 0.77 | HSPA5 (0.39) | KDM4EPOLBMAPT | |
| SCHEMBL11232342 | 0.76 | KDM4E (0.51) | SLC1A5KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1369142 | 0.74 | KDR (0.47) | MAPTHTT | |
| SCHEMBL1369034 | 0.73 | PTGDR2 (0.52) | TP53POLBGAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | SLC1A5 1415/4885KDM4E 4115/4885TP53 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.